Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia 2025-11-24T09:51:38-08:00November 24th, 2025| Read more
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib 2025-10-28T11:29:07-07:00September 3rd, 2025| Read more
A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML 2025-07-29T15:39:42-07:00July 29th, 2025| Read more
Performance Comparison of Illumina® MiSeq™ and MiSeq™ i100 Systems using Invivoscribe’s LymphoTrack® Assays 2025-09-18T16:16:23-07:00May 27th, 2025| Read more
From prognostication to precision in acute myeloid leukemia 2025-05-08T16:47:49-07:00May 8th, 2025| Read more
Invivoscribe Expands IVDR Portfolio with IdentiClone Dx IGH Assay Certification 2026-03-25T23:07:06-07:00March 25th, 2026| Read more
Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide 2026-02-05T14:09:13-08:00February 4th, 2026| Read more
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial 2026-03-09T18:04:28-07:00July 7th, 2025| Read more
LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials 2026-03-09T18:40:09-07:00June 17th, 2025| Read more
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay 2026-03-09T18:44:44-07:00April 22nd, 2025| Read more